Core Viewpoint - Recently, Stone Pharmaceutical Group (01093) has seen a significant stock price increase due to a strategic partnership with AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects outside of mainland China and Hong Kong/Macau [1] Group 1: Financial Details - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for development and sales [1] - The subsidiary of Giant Bio (New Nuo Wei, 300765) is entitled to receive 35% of the upfront payment and subsequent milestone payments based on actual conditions [1] Group 2: Future Prospects - CICC anticipates that by 2025, the company will have achieved external licensing for oral small molecule GLP-1 ($120 million upfront), AstraZeneca strategic cooperation ($110 million upfront), irinotecan liposome ($15 million upfront), and ROR1ADC ($15 million upfront) [1] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC/SiRNA series, which are expected to continue generating external licensing opportunities and milestone revenue recognition [1]

Core Viewpoint - The recent partnership between Stone Pharmaceutical Group and AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects is expected to significantly enhance the company's revenue potential through substantial upfront and milestone payments [1] Group 1: Financial Impact - Stone Pharmaceutical Group's stock rose over 5% in early trading, reflecting positive market sentiment regarding the AstraZeneca collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for the projects [1] - The company is projected to receive 35% of the initial payment from the collaboration, along with potential future milestone payments and royalties [1] Group 2: Development Pipeline - The company has successfully licensed out several projects, including oral small molecule GLP-1 and others, which are expected to generate significant revenue [1] - The research pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, indicating ongoing potential for further licensing agreements and milestone revenue recognition [1]

Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093) and raises target price by 9.1% to HKD 12, while keeping profit forecasts for 2025 and 2026 at CNY 4.76 billion and CNY 5.35 billion, respectively, and introducing a forecast of CNY 5.70 billion for 2027 [1] Group 1 - CSPC Pharmaceutical has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of eight innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [2] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative milestone payments for development and sales, with Giant Biologics (a subsidiary of New Horizon (300765)) entitled to 35% of the upfront payment and subsequent milestone payments [2] Group 2 - The company is betting on long-acting peptide drugs to compete in the weight loss and metabolic market, with its drug SYH2082 progressing to Phase I clinical trials as a monthly injection GLP1R/GIP agonist [3] - Pfizer's acquisition of Metsera for USD 10 billion highlights the competitive landscape, as Metsera's proprietary NuSH platform enables a long half-life for its weight loss drug MET-097 [3] Group 3 - CSPC has achieved significant external licensing agreements in 2025, including USD 120 million for oral small molecule GLP-1, USD 110 million for the AstraZeneca strategic partnership, and USD 15 million for ROR1ADC, indicating a trend towards regular income from external licensing [4] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, which are expected to lead to further successful licensing and milestone revenue recognition [4]

Company Updates - The company announced a research and development collaboration and licensing agreement with AstraZeneca for eight innovative long-acting peptide drug projects, including SYH2082 and three preclinical molecules, with an additional four projects under collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in development and sales milestone payments, with a subsidiary entitled to receive 35% of the upfront payment and subsequent milestone payments and royalties [1] Industry Insights - The collaboration marks a significant milestone for Chinese innovative drug licensing abroad, as multinational corporations (MNCs) are betting on long-acting peptide drugs to compete in the weight loss and metabolic market [1] - The company’s SYH2082 is a long-acting GLP1R/GIP agonist progressing to Phase I clinical trials, with expectations for more favorable efficacy and safety data [1] Revenue Generation - The company has achieved external licensing agreements in 2025, including $120 million for oral small molecule GLP-1, $110 million for the AstraZeneca collaboration, and $15 million for other projects, indicating a potential for regular income from licensing [2] - The company has a pipeline of innovative assets, including EGFR ADC/SiRNA series, which are expected to lead to further licensing agreements and milestone revenue recognition [2] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 is maintained at 4.76 billion yuan and 5.35 billion yuan, with an introduction of a 2027 forecast of 5.70 billion yuan [2] - The current stock price corresponds to a price-to-earnings ratio of 18.7 and 17.1 times for 2026 and 2027, respectively, with a target price adjustment of 9.1% to HKD 12.00, implying a 25% upside potential [2]

Investment Rating - The report maintains a neutral rating for the company with a target price of HKD 5.80, indicating a potential upside of 14.6% from the current price of HKD 5.06 [1][2][9]. Core Insights - The company's performance in Q4 2024 was negatively impacted by the procurement of Domperidone, but there is a noticeable improvement in the neurology segment. The raw material drug business continues to face slight pressure. It is anticipated that the impact of Domperidone procurement will stabilize entering 2025, with new product launches expected to drive revenue growth [2][6]. - The current forward P/E ratio is 11 times, with an estimated profit CAGR of 11% from 2024 to 2027, suggesting that the valuation is reasonable with limited upside potential [2][6]. - The company is expected to launch seven new products or indications in 2025, including significant approvals in the U.S. for certain drugs, which will help offset losses from procurement [6][7]. Financial Forecasts - Revenue projections for 2025 are set at RMB 29.6 billion, a slight decrease of 1.0% from previous estimates. The gross profit is forecasted at RMB 20.87 billion, reflecting a 3.8% decline [5][11]. - The net profit for 2025 is estimated at RMB 4.75 billion, down 4.4% from prior forecasts, with a net profit margin of 16.1% [5][11]. - The company anticipates a recovery in revenue for 2025, driven by stabilized inventory levels and the rapid market penetration of new products [6][11]. Stock Performance - The stock has shown a year-to-date change of +5.86%, with a 52-week high of HKD 7.12 and a low of HKD 4.34 [5][11]. - The average daily trading volume is reported at 214.03 million shares, indicating active trading interest [5][11]. Valuation Metrics - The DCF valuation model estimates the equity value at approximately RMB 60.89 billion, translating to a per-share value of HKD 5.80 [7][11]. - The company is currently trading at a P/E ratio of 11 times for 2025, with a PEG ratio of 1.0, suggesting that the stock is fairly valued [6][7].